Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
McDonald's China Faces Backlash for Food Hygiene Violations 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
ALWAYTH x Adidas Samba: Revolutionizing Sneaker Culture with Fashion-Forward Collaboration 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
How supermarkets are changing their branding to make you think they’re cheaper 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
GHENT, Belgium, June 16, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] issued a correction regarding a transparency notification received on 13 June 2016, pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007) concerning major holdings in Belgian listed companies.
Adrianus van Herk (not van Herk Investments as erroneously stated in the press release of 16 June 2016 at 07:00 am CET) notified Ablynx that he has exceeded the 3% threshold on 13 June 2016 and now holds 1,835,276 Ablynx shares, representing 3.02% of the current 60,870,926 outstanding Ablynx shares.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: [email protected]
pdf format of the press release http://hugin.info/137912/R/2021181/750845.pdf
HUG#2021181
